News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Yapan Bio, a contract development and manufacturing organization (CDMO) based in India, says it can now support end-to-end development and manufacturing of RNA, DNA and gene therapy products starting from plasmids.
Contract development and manufacturing organization (CDMO), Recipharm, has invested in a new high speed filling line for pre-filled syringes and cartridges at its facility in Wasserburg, Germany.
US gene therapy CDMO, Andelyn Biosciences, has opened a new GMP clinical and commercial manufacturing facility to support cell and gene therapy (CGT) development and manufacturing.
A new research consortium will develop better diagnostic tests, identify potential therapies, study vaccine effectiveness and track the virus’ spread.
Forge Biologics has added plasmid DNA manufacturing to its roster of services, enabling it to vertically integrate its production process.
The WHO has set out a new blueprint for dementia research: outlining the potential of precision medicine, repurposed drugs and revamped clinical trials. “Addressing dementia is one of the greatest health challenges of our generation,” says the organization.